🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the battle against drug-resistant strains of the pathogen, according to scientists.

A Worldwide Public Health Issue

Gonorrhoea infections are escalating around the world, with estimates suggesting in excess of 82 million infections per year. Notably increased rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an critical and opportune development in the reality of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options currently available.”

Medical experts are increasingly worried about the increase in drug-resistant strains. The WHO has classified it as a "critical concern". Ongoing monitoring revealed that the effectiveness of standard treatments like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Receive Approval

One new antibiotic, also known as Nuzolvence, was approved by the US FDA in mid-December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Scientists hope that targeted use of this new drug will help delay the spread of drug resistance.

Another new antibiotic, developed by the pharmaceutical company GSK, was also approved in close succession. This treatment, which is employed against urinary tract infections, was demonstrated in studies to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

This new treatment emerged from a innovative non-profit model for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to bring it to fruition.

“This milestone represents a major breakthrough in the management of superbug gonorrhoea, which previously has been staying ahead of medical innovation.”

Testing Results and Worldwide Availability

As per findings published in a prominent scientific publication, the new drug eradicated the vast majority of genital gonorrhoea infections. This establishes an similar efficacy with the current standard treatment, which involves a dual-drug approach. The research enrolled over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its unique model, the non-profit has the authority to license and sell the drug in numerous low-income and middle-income countries.

Clinicians directly involved have expressed positive views. Access to a single-dose, oral treatment of this kind is described as a "critical tool" for gonorrhoea control. This is considered crucial to alleviate the strain of the illness for individuals and to prevent the spread of extremely resistant gonorrhoea worldwide.